Interleukin-13 level accompanying with Helicobacter pylori gastric infection in Kirkuk city
Article Sidebar
Main Article Content
Abstract
Background: Helicobacter pylori recognized as the most common cause of chronic gastritis and an important pathogenic factor in peptic ulcer, after colonization and stomach mucus layers caused increase in the levels of anti-inflammatory cytokine such as IL-13.
The aims of this study is compare of IL-13 levels among treated patients with H. Pylori gastric infection, patients with H. Pylori gastric infection without treatment and healthy person
Materials and Methods: The study was conducted in Kirkuk city from the September 2020 to March 2020, ELISA test used for interleukin -13 with peptic ulcer diseases (PUD).
Results: Elevated levels of IL-13 reported in patients with acute and chronic H. pylori gastric infection compared to control group (44.74+8.18). A moderate significant in IL-13 level determined in infected patients without treatment, previously treated patients (140.12+45.36 vs 105+22.71). While, there was a high significant difference when these two groups and compared with the control group (44.74+8.18)).
Conclusion: IL-13 levels is highest in patients with H. pylori gastric infection in compare healthy person.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
[1] Gravina, A. G.; Zagari, R. M.; De Musis, C.; Romano, L.; Loguercio, C. and Romano, M. (2018). Helicobacter pylori and extragastric diseases: a review. World journal of gastroenterology, 24 (29), 3204-3221.
[2] Nisa, S. (2018). Gastritis (Warm-e-meda): A review with Unani approach. Int. J. Adv. Sci. Res,3 (3), 43-45.
[3] Suzuki, H. and Mori, H. (2015). Helicobacter pylori gastritis—a novel distinct disease entity. Nature reviews Gastroenterology & hepatology, 12 (10), 556-557.
[4] Kuna, L.; Jakab, J.; Smolic, R.; Raguz-Lucic, N.; Vcev, A. and Smolic, M. (2019). Peptic ulcer disease: a brief review of conventional therapy and herbal treatment options. Journal of clinical medicine, 8 (2), 1-19.
[5] Khadka, A. (2014). Interleukins in therapeutics. Pharma Tutor, 2 (4), 67 72.
[6] Giuffrida, P.; Caprioli, F.; Facciotti, F. and Di Sabatino, A. (2019). The role of interleukin-13 in chronic inflammatory intestinal disorders. Autoimmunity reviews, 18 (5), 549-555.
[7] Mannon, P. and Reinisch, W. (2012). Interleukin 13 and its role in gut defence and inflammation. Gut, 61 (12), 1765-1773. [8] Chen, J., Bu, X. L., Wang, Q. Y., Hu, P. J., & Chen, M. H. (2007). Decreasing seroprevalence of Helicobacter pylori infection during 1993–2003 in Guangzhou, southern China. Helicobacter, 12 (2), 164-169.
[9] Marotti, B.; Rocco, A.; De Colibus, P.; Compare, D.; de Nucci, G.; Staibano, S. and Nardone, G. (2008). Interleukin-13 mucosal production in Helicobacter pylori-related gastric diseases. Digestive and Liver Disease, 40 (4), 240-247.
[10] Thomson, A. B. R.; Appleman, S.; Keelan, M. and Wallace, J. L. (2003). Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa. Digestive diseases and sciences, 48 (2), 308-314.
[11] Eskandari - Nasab, E.; Sepanjnia, A.; Moghadampour, M.; Hadadi-Fishani, M.; Rezaeifar, A.; Asadi-Saghandi, A. and Pourmasoumi, H. (2013). Circulating levels of interleukin (IL)-12 and IL-13 in Helicobacter pylori-infected patients, and their associations with bacterial CagA and VacA virulence factors. Scandinavian journal of infectious diseases, 45(5), 342-349. [12] Romagnani, S. (1999). Th1/th2 cells. Inflammatory bowel diseases, 5(4), 285-294.
[13] Tanabe, T.; Kanoh, S.; Tsushima, K.; Yamazaki, Y.; Kubo, K. and Rubin, B. K. (2011). Clarithromycin inhibits interleukin-13–induced goblet cell hyperplasia in human airway cells. American Journal of Respiratory Cell and Molecular Biology, 45 (5), 1075-1083.
[14] Komiya, K.; Ohta, S.; Arima, K.; Ogawa, M.; Suzuki, S.; Mitamura, Y. and Izuhara, K. (2017). Clarithromycin attenuates IL-13–induced periostin production in human lung fibroblasts. Respiratory research, 18 (1), 1-8. [15] Molina‐Infante, J.; Rivas, M. D.; Hernandez‐Alonso, M.; Vinagre‐Rodríguez, G.; Mateos‐Rodríguez, J. M.; Dueñas‐Sadornil, C. and Zamorano, J. (2014). Proton pump inhibitor‐responsive oesophageal eosinophilia correlates with downregulation of eotaxin‐3 and Th2 cytokines overexpression. Alimentary pharmacology & therapeutics, 40 (8), 955-965.